NO20054868L - CaSr antagonist - Google Patents

CaSr antagonist

Info

Publication number
NO20054868L
NO20054868L NO20054868A NO20054868A NO20054868L NO 20054868 L NO20054868 L NO 20054868L NO 20054868 A NO20054868 A NO 20054868A NO 20054868 A NO20054868 A NO 20054868A NO 20054868 L NO20054868 L NO 20054868L
Authority
NO
Norway
Prior art keywords
compound
calcium
casr antagonist
antagonist
osteoporosis
Prior art date
Application number
NO20054868A
Other languages
English (en)
Other versions
NO20054868D0 (no
Inventor
Yuko Shinagawa
Teruhiko Inoue
Toshihiro Kiguchi
Taku Ikenogami
Naoki Ogawa
Kenji Fukuda
Takashi Nakagawa
Masanori Shindo
Yuki Soejima
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of NO20054868D0 publication Critical patent/NO20054868D0/no
Publication of NO20054868L publication Critical patent/NO20054868L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)

Abstract

Det beskrives en forbindelse som representeres ved den generelle formel (1) samt farmasøytisk akseptable salter eller optisk aktive former derav, der hvert symbol er som definert. Forbindelsene har en kalsiumfølende reseptorantagonistisk virkning. Det beskrives videre farmasøytiske preparater omfattende forbindelsen og særlig en kalsiumreseptorantagonist, og et terapeutisk medikament mot osteoporose.
NO20054868A 2003-04-23 2005-10-21 CaSr antagonist NO20054868L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003119131 2003-04-23
PCT/JP2004/005886 WO2004094362A1 (ja) 2003-04-23 2004-04-23 CaSRアンタゴニスト

Publications (2)

Publication Number Publication Date
NO20054868D0 NO20054868D0 (no) 2005-10-21
NO20054868L true NO20054868L (no) 2005-12-20

Family

ID=33308093

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054868A NO20054868L (no) 2003-04-23 2005-10-21 CaSr antagonist

Country Status (31)

Country Link
US (4) US7304174B2 (no)
EP (3) EP1619180B1 (no)
JP (1) JP3751312B2 (no)
KR (1) KR100696927B1 (no)
CN (2) CN100577633C (no)
AR (1) AR044075A1 (no)
AT (1) ATE452121T1 (no)
AU (1) AU2004232604C1 (no)
BR (1) BRPI0407097A (no)
CA (1) CA2513738C (no)
CL (1) CL2004000868A1 (no)
CO (1) CO5640091A2 (no)
CY (1) CY1109880T1 (no)
DE (1) DE602004024668D1 (no)
DK (1) DK1619180T3 (no)
ES (1) ES2337576T3 (no)
HK (1) HK1083096A1 (no)
HR (1) HRP20100042T1 (no)
IL (1) IL169575A (no)
MX (1) MXPA05007609A (no)
MY (1) MY138734A (no)
NO (1) NO20054868L (no)
NZ (1) NZ541188A (no)
PE (1) PE20050460A1 (no)
PL (1) PL1619180T3 (no)
PT (1) PT1619180E (no)
RU (1) RU2315036C2 (no)
SI (1) SI1619180T1 (no)
TW (1) TWI329628B (no)
WO (1) WO2004094362A1 (no)
ZA (1) ZA200505587B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
JPWO2004106280A1 (ja) * 2003-05-28 2006-07-20 日本たばこ産業株式会社 ＣａＳＲアンタゴニスト
EP1713758A4 (en) * 2004-02-06 2008-02-13 Smithkline Beecham Corp CALCILYTIC COMPOUNDS
CA2648939C (en) * 2006-04-20 2014-07-08 Amgen Inc. Stable emulsion formulations
AU2008233088B2 (en) 2007-03-30 2013-09-26 Amgen Inc. Calcimimetic compounds for use in the treatment of bowel disorders
DK2292592T3 (da) * 2008-06-05 2012-10-08 Asahi Kasei Pharma Corp Sulfonamidforbindelse og anvendelse deraf
CA2748250A1 (en) * 2008-12-24 2010-07-01 Daiichi Sankyo Company, Limited Indanyl compounds
CA2748249C (en) 2008-12-24 2013-07-02 Daiichi Sankyo Company, Limited Cyclic amine compounds
WO2010103429A1 (en) * 2009-03-10 2010-09-16 Pfizer Inc. 1,1-(Dimethyl-Ethylamino)-2-Hydroxy-Propoxy]-Ethyl}-3-Methyl-Biphenyl-4- Carboxylic Acid Derivatives As Calcium Receptor Antagonists
WO2010104882A1 (en) 2009-03-10 2010-09-16 Amgen Inc. Methods of modulating sperm motility
EP2412697A1 (en) * 2009-03-26 2012-02-01 Japan Tobacco, Inc. Process for producing carboxylic acid compound
WO2010113860A1 (ja) * 2009-03-31 2010-10-07 第一三共株式会社 ビフェニル－環状アミン化合物
JP2012528084A (ja) 2009-05-27 2012-11-12 レオ ファーマ アクティーゼルスカブ 新規のカルシウム感知受容体調節化合物およびその医薬用途
EP2435404A1 (en) 2009-05-27 2012-04-04 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
WO2012069419A1 (en) 2010-11-26 2012-05-31 Leo Pharma A/S Calcium-sensing receptor-active compounds
CN103228619A (zh) 2010-11-26 2013-07-31 利奥制药有限公司 钙传感受体活性化合物
WO2012069402A1 (en) 2010-11-26 2012-05-31 Leo Pharma A/S Substituted cyclopentyl - azines as casr- active compounds
JP2014507375A (ja) 2010-11-26 2014-03-27 レオ ファーマ アクティーゼルスカブ カルシウム感知受容体活性化合物
GB201113538D0 (en) * 2011-08-04 2011-09-21 Karobio Ab Novel estrogen receptor ligands
IN2015MN00421A (no) * 2012-08-27 2015-09-04 Lupin Ltd
CA3027290A1 (en) 2016-06-13 2017-12-21 Syneurx International (Taiwan) Corp. Use of lithium benzoate for treating central nervous system disorders
MX2022006892A (es) * 2019-12-09 2022-10-07 Beijing Tuo Jie Biopharmaceutical Co Ltd Compuesto agonista del receptor sensor de calcio y aplicación del mismo.
IL300285A (en) 2020-08-04 2023-04-01 Calcilytix Therapeutics Inc Formulations of triphenyl calcilytic compounds
MX2023003129A (es) * 2020-09-18 2023-08-04 Calcilytix Therapeutics Inc Compuestos trifenil-calciliticos para el tratamiento de hipocalcemia autosomica dominante tipo 1 (adh1).

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE633760A (no) * 1963-06-18
DD207203A1 (de) * 1982-06-21 1984-02-22 Peter Meisel Verfahren zur herstellung von epoxypropylethern
DE3743265A1 (de) * 1987-12-19 1989-06-29 Boehringer Ingelheim Kg Neue ammoniumverbindungen, ihre herstellung und verwendung
US5276008A (en) * 1990-08-09 1994-01-04 Bayer Aktiengesellschaft Substituted 4,5-diamino-1,2,4-triazol-3-(thi)ones
NZ332068A (en) 1996-04-09 2001-03-30 Smithkline Beecham Alpha, alpha-disubstituted arylalkylamine derivatives as calcilytic compounds
US6818660B2 (en) 1996-04-09 2004-11-16 Nps Pharmaceuticals, Inc. Calcilytic compounds
ATE215369T1 (de) * 1996-09-05 2002-04-15 Lilly Co Eli Carbazolanaloge als selektive beta3-adrenergische agonisten
UY24949A1 (es) * 1997-04-08 2001-04-30 Smithkline Beecham Corp Compuestos calcilíticos
US20020052509A1 (en) 1998-04-08 2002-05-02 Smithkline Beecham Corporation Calcilytic compounds and method of use
PE20000415A1 (es) 1998-04-08 2000-05-21 Smithkline Beecham Corp Compuestos calciliticos
AR014975A1 (es) 1998-04-08 2001-04-11 Nps Pharma Inc Compuestos calciliticos, una composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de un medicamento
US6334338B1 (en) * 1998-07-02 2002-01-01 Lucent Technologies Inc. Sol gel process of making a fiber preform with removal of oxide particles
JP2002522499A (ja) 1998-08-12 2002-07-23 スミスクライン・ビーチャム・コーポレイション カルシウム分解化合物
EP1104411A4 (en) 1998-08-12 2002-10-24 Smithkline Beecham Corp CALCILYTIC COMPOUNDS
JP3593035B2 (ja) * 1998-10-23 2004-11-24 エフ．ホフマン−ラ ロシュ アーゲー 二環式窒素複素環化合物
PE20001456A1 (es) 1999-02-02 2001-01-28 Smithkline Beecham Corp Compuestos calcioliticos
EP1206520A1 (en) * 1999-08-27 2002-05-22 The Procter & Gamble Company Fast-acting formulation components, compositions and laundry methods employing same
IL152925A (en) 1999-10-21 2010-04-15 Pfizer Pharmaceutical preparations for the treatment of neurological disease containing an inhibitor of ring guanizine '3', 5 '- monophosphate phosphodiesterase 5 and one of gabapentin or pregabalin
MY159417A (en) 2000-01-24 2017-01-13 Smithkline Beecham Corp Calcilytic compounds
US20030018203A1 (en) * 2002-07-17 2003-01-23 Largo Maria Amparo Calcilytic compounds
US6867299B2 (en) * 2000-02-24 2005-03-15 Hoffmann-La Roche Inc. Oxamide IMPDH inhibitors
KR20030017642A (ko) 2000-07-21 2003-03-03 스미스클라인 비참 코포레이션 칼실리틱 화합물
US6916956B2 (en) * 2000-08-11 2005-07-12 Japan Tobacco, Inc. Calcium receptor antagonist
EP1383511B1 (en) 2000-10-25 2006-10-25 SmithKline Beecham Corporation Calcilytic compounds
EP1404654A4 (en) 2000-10-25 2008-12-03 Smithkline Beecham Corp CALCILYTIC COMPOUNDS
AR038658A1 (es) 2001-06-15 2005-01-26 Novartis Ag Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento
US6864267B2 (en) 2001-07-16 2005-03-08 Smithkline Beecham Corporation Calcilytic compounds
JPWO2004106280A1 (ja) * 2003-05-28 2006-07-20 日本たばこ産業株式会社 ＣａＳＲアンタゴニスト

Also Published As

Publication number Publication date
BRPI0407097A (pt) 2006-01-24
JPWO2004094362A1 (ja) 2006-07-13
EP1619180A1 (en) 2006-01-25
TW200505823A (en) 2005-02-16
NZ541188A (en) 2008-01-31
DK1619180T3 (da) 2010-03-29
IL169575A0 (en) 2007-07-04
DE602004024668D1 (de) 2010-01-28
EP2308828A2 (en) 2011-04-13
RU2005123985A (ru) 2006-01-27
IL169575A (en) 2011-07-31
CN1741984A (zh) 2006-03-01
AU2004232604C1 (en) 2008-06-05
US7304174B2 (en) 2007-12-04
HK1083096A1 (en) 2006-06-23
AU2004232604B8 (en) 2004-11-04
EP2189439A3 (en) 2011-05-04
AU2004232604A1 (en) 2004-11-04
AR044075A1 (es) 2005-08-24
US20050032796A1 (en) 2005-02-10
NO20054868D0 (no) 2005-10-21
EP1619180B1 (en) 2009-12-16
CY1109880T1 (el) 2014-09-10
ATE452121T1 (de) 2010-01-15
RU2315036C2 (ru) 2008-01-20
CO5640091A2 (es) 2006-05-31
US20080255042A1 (en) 2008-10-16
PE20050460A1 (es) 2005-07-08
ZA200505587B (en) 2006-09-27
KR100696927B1 (ko) 2007-03-20
JP3751312B2 (ja) 2006-03-01
CL2004000868A1 (es) 2005-01-21
US20090326058A1 (en) 2009-12-31
CN101723921A (zh) 2010-06-09
ES2337576T3 (es) 2010-04-27
MY138734A (en) 2009-07-31
EP1619180A4 (en) 2006-05-24
PT1619180E (pt) 2009-12-29
AU2004232604B2 (en) 2007-09-13
US20120301552A1 (en) 2012-11-29
TWI329628B (en) 2010-09-01
EP2189439A2 (en) 2010-05-26
SI1619180T1 (sl) 2010-04-30
KR20050094047A (ko) 2005-09-26
CA2513738C (en) 2010-04-06
HRP20100042T1 (hr) 2010-02-28
CA2513738A1 (en) 2004-11-04
CN100577633C (zh) 2010-01-06
WO2004094362A1 (ja) 2004-11-04
EP2308828A3 (en) 2013-05-22
PL1619180T3 (pl) 2010-05-31
MXPA05007609A (es) 2005-09-30
AU2004232604A8 (en) 2004-11-04

Similar Documents

Publication Publication Date Title
NO20054868L (no) CaSr antagonist
ATE397605T1 (de) Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
SE0302760D0 (sv) New compounds
NO20042811L (no) Substituerte henzoksazoler og analoger som estrogene midler
ECSP034744A (es) Antagonistas de nmda/nr2b no arilo-heterociclico n-sustituidos
NO20045486L (no) Nye forbindelser og deres anvendelse
NO20062691L (no) Azabicykliske heterocykler som cannabinoide reseptormodulatorer
TW200714583A (en) Substituted gamma lactams as therapeutic agents
NO20062061L (no) Nye substituerte, 4-amino-tiazolo[4,5-D]pyriminder, nyttige som kjemokinreseptorantagonister, ESP. CX3CR1
NO20062689L (no) Azabisykliske heterosykler som modulatorer for kannabinoidreseptorer
CO5580767A2 (es) Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso
NO20064078L (no) Substituerte azetidinsammensetninger, deres fremstilling og anvendelse som medikamenter
NO20072939L (no) Makroloner - aminosubstituerte kinoloner
NO20040881L (no) Orale antidiabetes midler.
DE60302157D1 (de) Opioidrezeptorantagonisten
DK1511489T3 (da) Nye farmaceutiske sammensætninger indeholdende flibanserin-polymorf A
DE60322680D1 (de) Opioid-rezeptor-aktive 4-(3-hydroxyphenyl) oder 4-(3-alkoxyphenyl)-1,2,4-triazol-verbindungen
PA8568101A1 (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso
NO20052491L (no) Nye vitronektinresepotr antagonistderivater, fremgangsmate til deres fremstilling, anvendelse derav som legemidler og farmasoytiske sammensetninger som inneholder de samme
NO20080669L (no) Acetylenpiperaziner som metabotrofiske glutamatreseptorantagonister
DE60225694D1 (de) Fexofenadine hydrochlorid polymorph
NO20044531L (no) Imidazolinylmetyl-aralkylsulfonamider, blandinger omfattende slike, fremgangsmate for fremstilling av slike, slike forbindelser som medikament samt anvendelse av slike forbindelser for fremstilling av medikamenter for behandling av sykdom
NO20063790L (no) Substituerte azetidin sammensetninger som cyclooxygenase-1-cyclooxygenase-2-inhibitorer, og deres fremstilling og anvendelse som medikamenter
BRPI0513549A (pt) composições farmacêuticas para o tratamento de leishmaniose

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application